Artica (Hydroxyzine) is primarily used for symptomatic relief across major therapeutic domains.

---

Main Therapeutic Uses and Patient Benefit

This medication is commonly used to provide support for distressing symptoms associated with anxiety and generalized tension (such as excessive worry and inner restlessness), and for the management of pruritus (intense itching) resulting from allergic dermatological conditions like chronic urticaria. Additionally, it is relevant in contexts involving heightened systemic burden, often applied as a sedative to support pre-procedure calm.

It is used for managing conditions characterized by periods of heightened symptoms, including the symptomatic relief of anxiety, management of allergic pruritus, and short-term adjunctive sedation. The medication provides support that helps ease the overall symptom burden by offering symptomatic relief across domains of tension and physical discomfort. This supportive function assists with coping more steadily with intense itching and restlessness and is applied during phases when symptoms become more noticeable.

Quick Fact: Relief for Dual Discomfort
Artica is relevant for easing symptoms related to heightened physiological activity (tension) and inflammatory or irritative states (itching), supporting patients where these symptom clusters may occur together.

---

Regulatory References

1. NIH MedlinePlus Drug Information

️ Final Eligibility Assessment: Who Can and Cannot Use Artica

The eligibility to use Artica (Hydroxyzine) is strictly defined by regulatory documents, which establish mandatory contraindications and population-specific restrictions.

Absolute Contraindications

The medicine is contraindicated (must not be used) in several patient populations:

• Patients with known hypersensitivity to hydroxyzine, its metabolites (cetirizine, levocetirizine), or related piperazine derivatives.
• Individuals with a known acquired or congenital QT interval prolongation or certain cardiac risk factors like significant bradycardia or hypokalemia.
• Patients diagnosed with porphyria.
• Women in early pregnancy.

Population Restrictions and Cautions

Population Group	Regulatory Status
Older Adults	Use is not recommended by some regulators; if used, the maximum daily dose is restricted (e.g., to 50 mg).
Severe Hepatic Impairment	Use must be avoided or requires a mandatory dose reduction in cases of impairment.
Moderate/Severe Renal Impairment	Use requires caution and a dose reduction is mandatory due to altered drug elimination.
Breastfeeding	Not recommended; mothers must discontinue breastfeeding if therapy is required.
Children Under 12 Months	Safety and efficacy have not yet been established for all formulations.

Use also requires caution in patients with pre-existing heart disease, glaucoma, bladder outflow obstruction, or myasthenia gravis, due to potential risk factors cited in regulatory labeling.

Artica Interactions with other medicines and products

Artica (Hydroxyzine) has documented interactions with several medicinal product categories and substances, according to official regulatory labeling. These interactions are classified by regulatory authorities based on their potential to alter drug exposure or result in additive effects.

Interaction Type	Examples of Interacting Medicines or Products
Formally Contraindicated Combinations	QT/QTc-prolonging drugs (e.g., Amiodarone, Quinidine, Azithromycin), potent CYP3A4/5 inhibitors
Pharmacodynamic Potentiation	Central Nervous System (CNS) depressants (e.g., Narcotics, Hypnotics, Barbiturates), Anticholinergic agents
Metabolic Interactions	CYP3A4/5 Inhibitors (increase Artica exposure), CYP3A4/5 Inducers (decrease exposure), Cimetidine (increases Artica concentration)
Other Pharmacodynamic Effects	Adrenaline (Epinephrine) (Artica inhibits vasopressor effect), Betahistine (Artica may antagonise effects)

Combinations with potent CYP3A4/5 inhibitors are prohibited as they can increase Artica's concentration in the body. Simultaneous use of medicines that prolong the QTc interval is also strictly contraindicated due to the risk of cardiac rhythm abnormalities.

Official labeling specifically notes that the effects of alcohol may be increased by Artica, and caution is advised regarding grapefruit or grapefruit-containing products. Additionally, regulatory documents highlight that interaction severity may be heightened in certain populations, recommending avoidance or close monitoring in elderly patients and those with severe hepatic impairment.

How Artica Works

Artica's mechanism of action is defined by a non-selective binding profile that influences key signaling dynamics in both the central nervous system (CNS) and peripheral pathways. The molecule functions as a competitive antagonist at several G-protein coupled receptors.

Central Nervous System Suppression and Arousal Modulation

Artica acts on the CNS by blocking Histamine mathbfH1 receptors and Serotonin mathbf5-HT2 A receptors in the brain. This antagonism rapidly dampens neuronal activity in subcortical structures, including the limbic system and the ascending pathways that govern alertness. This suppression of arousal-related signaling results in a state of central nervous system depression, which defines the drug’s overall CNS physiological profile.

Peripheral Interference with Inflammatory Mediators

In the periphery, the drug acts as a competitive mathbfH1 antagonist to block the action of endogenously released histamine. This suppression interrupts the molecular cascade that triggers increased capillary permeability, localized swelling, and the stimulation of afferent sensory nerve fibers. This interaction thus modulates the physiological cascade initiated by peripheral histamine activation.

How to Use Artica: Official Administration Guidelines

Artica (Hydroxyzine) is used according to specific administration patterns, focusing on specific routes, dosage ranges, and patient populations. The medicine is primarily administered via the oral route as tablets, capsules, or syrup for ongoing symptomatic management. The injectable solution is used for deep intramuscular (IM) injection in clinical settings and is not to be administered intravenously or subcutaneously.

Standard Dosing and Frequency

Dosage is structured based on the condition being managed. For the management of pruritus (itching), the typical adult oral regimen involves 25 mg administered three or four times daily in divided doses. For the symptomatic treatment of anxiety, adult dosing often ranges from 50 mg to 100 mg total per day, also given in divided doses. A single, higher dose is used for pre- or post-procedure sedation.

Contextual Use and Adjustments

Oral forms may be taken with or without food; the option to take with food is provided if gastric upset occurs. For chronic use, the need for continued treatment is periodically reassessed, as systematic data for efficacy may be limited beyond a few months. Specific dose modifications are utilized for vulnerable populations. For instance, the maximum total daily dose for older adults is reduced in many regions, often to 50 mg. Furthermore, individuals with impaired kidney or liver function require a lower initial dose and a reduction in the standard maintenance dose or an extension of the dosing interval, adhering to pharmacokinetics-based recommendations.

Research evidence / Overview of studies for Artica (Hydroxyzine)

The information below summarizes the clinical research and evidence base for Artica (Hydroxyzine) as reported in official and peer-reviewed scientific sources.

---

Evidence for Symptomatic Relief of Anxiety and Tension

Research related to this use focused on short-term Randomized Controlled Trials (RCTs) and systematic reviews examining adult populations with conditions characterized by fluctuating or episodic manifestations of anxiety and tension. In these research contexts, scientists studied how symptom measurements were taken when Artica was used for anxiety and tension, compared to an inactive substance (placebo) or other medicines used for anxiety evaluation.

Researchers monitored outcomes reflecting daily functioning or activity level and utilized standardized rating scales, such as the HAM-A. The findings observed in the studies described patterns related to the measurements taken on anxiety scale scores over defined, short time intervals, typically lasting a few weeks to a few months.

However, a key limitation noted in the research landscape is that follow-up durations were limited. There is limited information for long-term outcomes, as the systematic clinical studies were not conducted to assess patterns of use or symptom changes over periods exceeding approximately four months.

---

Evidence for Managing Allergic Pruritus (Itching)

The evidence base for managing persistent itching, which is an outcome linked to inflammatory or irritative states, is supported by multiple RCTs and comparative studies. This research was applied in studies examining patient-reported experiences of itching in both adults and children with allergic conditions. The studies explored changes in the intensity of itching and how this related to outcomes reflecting daily functioning or activity level, often assessed using quality-of-life questionnaires.

The data gathered during these research scenarios showed patterns related to measurable severity of outcomes related to physical discomfort. The consistency of these reported findings is documented in the evidence landscape for these conditions, and is recognized in guideline summaries of available research.

---

What is Still Uncertain About Artica's Research

A primary limitation is the lack of established long-term effects in the clinical trials for its evaluation in anxiety and tension; the long-term outcomes are not fully established, and the follow-up durations were limited. Additionally, evidence quality varies across studies, and while findings describe group patterns, research does not determine whether an individual will respond similarly.

Common questions about Artica (FAQ)

Q: What is the active ingredient in Artica, and what type of drug is it?

A: Artica contains Articaine hydrochloride and epinephrine (adrenaline) as its active ingredients. According to official product information, it is classified as a local anesthetic, which is a medicine used to cause temporary loss of sensation in a specific area of the body.

Q: Does Artica contain preservatives?

A: Regulatory documents state that Artica solution for injection typically does not contain sulfites or other preservatives in the formulation. This means that the absence of these ingredients is characteristic of the official product information for the medicine.

Q: What is Artica used for?

A: Artica is primarily used to achieve local anesthesia for simple and complex procedures in dentistry. This means it is administered to numb a specific area of the mouth to prevent pain during dental treatment. Official information indicates this as its intended use.

Q: How quickly does Artica start working?

A: According to the official product information, Artica has a rapid onset of action. This means that the numbing effect is reported to begin quickly, typically within a few minutes following administration by a healthcare professional.

Q: How long does the numbing effect of Artica last?

A: The expected duration of anesthesia, according to official information, can range from about one hour up to several hours. The exact time depends on the specific formulation administered, the amount used, and whether soft-tissue anesthesia is required for the procedure being performed.

Q: Can Artica be used in patients with asthma?

A: Regulatory documents state that the use of Artica requires caution in patients with asthma. The product information notes that the ingredient epinephrine, a vasoconstrictor, is a reason for caution, particularly in those with certain severe respiratory conditions or sensitivities.

Q: Can Artica be used in patients with heart conditions?

A: According to the official product information, extreme caution is necessary when Artica is used in patients with certain severe cardiovascular conditions. Official documentation specifies that a careful assessment of risks is required by the healthcare provider before Artica is administered to these patients.

Q: Is Artica safe to use during pregnancy?

A: Official product information states that caution should be exercised when considering the use of Artica during pregnancy. Regulatory documents require that the potential benefits must be weighed against any possible risk to the fetus by a healthcare provider before deciding on its use.

Q: Is Artica safe to use while breastfeeding?

A: Studies and official information indicate that the excretion of Articaine and its components into breast milk is low following dental use. Therefore, the final decision regarding its use while breastfeeding is made by the healthcare provider, who considers the overall risk and benefit.

Storage and Protection Requirements

Artica must be stored at Controlled Room Temperature, which is between 20 C and 25 C (68 F and 77 F). The medication must be kept away from excess heat and moisture and should not be stored in a bathroom.

The container must be kept tightly closed and should be light-resistant for certain forms. To ensure the medication's integrity, it must not be used after the printed expiry date.

Child Safety and Disposal

All forms of Artica must be kept out of the sight and reach of children.

Disposal must follow regulatory instructions. Medicines should not be disposed of in wastewater or household waste. Unused or expired medication should be taken to a drug take-back program or, if unavailable, securely mixed with an undesirable substance (such as dirt) and placed in a sealed bag for disposal in household trash.